241 related articles for article (PubMed ID: 27858708)
21. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
Mattsson-Carlgren N; Grinberg LT; Boxer A; Ossenkoppele R; Jonsson M; Seeley W; Ehrenberg A; Spina S; Janelidze S; Rojas-Martinex J; Rosen H; La Joie R; Lesman-Segev O; Iaccarino L; Kollmorgen G; Ljubenkov P; Eichenlaub U; Gorno-Tempini ML; Miller B; Hansson O; Rabinovici GD
Neurology; 2022 Mar; 98(11):e1137-e1150. PubMed ID: 35173015
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.
Rivero-Santana A; Ferreira D; Perestelo-Pérez L; Westman E; Wahlund LO; Sarría A; Serrano-Aguilar P
J Alzheimers Dis; 2017; 55(2):625-644. PubMed ID: 27716663
[TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
[TBL] [Abstract][Full Text] [Related]
24. Typical and atypical pathology in primary progressive aphasia variants.
Spinelli EG; Mandelli ML; Miller ZA; Santos-Santos MA; Wilson SM; Agosta F; Grinberg LT; Huang EJ; Trojanowski JQ; Meyer M; Henry ML; Comi G; Rabinovici G; Rosen HJ; Filippi M; Miller BL; Seeley WW; Gorno-Tempini ML
Ann Neurol; 2017 Mar; 81(3):430-443. PubMed ID: 28133816
[TBL] [Abstract][Full Text] [Related]
25. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias.
Steinacker P; Semler E; Anderl-Straub S; Diehl-Schmid J; Schroeter ML; Uttner I; Foerstl H; Landwehrmeyer B; von Arnim CA; Kassubek J; Oeckl P; Huppertz HJ; Fassbender K; Fliessbach K; Prudlo J; Roßmeier C; Kornhuber J; Schneider A; Volk AE; Lauer M; Danek A; Ludolph AC; Otto M;
Neurology; 2017 Mar; 88(10):961-969. PubMed ID: 28179468
[TBL] [Abstract][Full Text] [Related]
26. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest.
Foiani MS; Cicognola C; Ermann N; Woollacott IOC; Heller C; Heslegrave AJ; Keshavan A; Paterson RW; Ye K; Kornhuber J; Fox NC; Schott JM; Warren JD; Lewczuk P; Zetterberg H; Blennow K; Höglund K; Rohrer JD
J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):740-746. PubMed ID: 30981993
[TBL] [Abstract][Full Text] [Related]
27. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders.
Bourbouli M; Rentzos M; Bougea A; Zouvelou V; Constantinides VC; Zaganas I; Evdokimidis I; Kapaki E; Paraskevas GP
Dement Geriatr Cogn Disord; 2017; 44(3-4):144-152. PubMed ID: 28848086
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
30. Distinct brain perfusion pattern associated with CSF biomarkers profile in primary progressive aphasia.
Kas A; Uspenskaya O; Lamari F; de Souza LC; Habert MO; Dubois B; Teichmann M; Sarazin M
J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):695-8. PubMed ID: 22665450
[TBL] [Abstract][Full Text] [Related]
31. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
Mulder C; Verwey NA; van der Flier WM; Bouwman FH; Kok A; van Elk EJ; Scheltens P; Blankenstein MA
Clin Chem; 2010 Feb; 56(2):248-53. PubMed ID: 19833838
[TBL] [Abstract][Full Text] [Related]
32. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid markers detect Alzheimer's disease in nonamnestic dementia.
Oboudiyat C; Gefen T; Varelas E; Weintraub S; Rogalski E; Bigio EH; Mesulam MM
Alzheimers Dement; 2017 May; 13(5):598-601. PubMed ID: 28196768
[TBL] [Abstract][Full Text] [Related]
34. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.
Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA
J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.
Ossenkoppele R; Mattsson N; Teunissen CE; Barkhof F; Pijnenburg Y; Scheltens P; van der Flier WM; Rabinovici GD
Neurobiol Aging; 2015 Aug; 36(8):2340-7. PubMed ID: 25990306
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
38. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
39. Prediction of pathology in primary progressive language and speech disorders.
Deramecourt V; Lebert F; Debachy B; Mackowiak-Cordoliani MA; Bombois S; Kerdraon O; Buée L; Maurage CA; Pasquier F
Neurology; 2010 Jan; 74(1):42-9. PubMed ID: 19940270
[TBL] [Abstract][Full Text] [Related]
40. Role of Cerebrospinal Fluid Biomarkers and (18)F-florbetapir PET Imaging in the Diagnosis of Primary Progressive Aphasia: A Retrospective Analysis.
Perini G; Cotta Ramusino M; Sinforiani E; Franciotta D; Trifirò G; Ceroni M; Costa A
Alzheimer Dis Assoc Disord; 2019; 33(3):282-284. PubMed ID: 30640253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
